Research programme: small molecule therapeutics - Quimatryx

Drug Profile

Research programme: small molecule therapeutics - Quimatryx

Alternative Names: DNA methyltransferase inhibitors - Quimatryx; DNMT inhibitors - Quimatryx; HDAC inhibitor - Quimatryx; HDAC pan-inhibitor - Quimatryx; HDAC2 selective inhibitor - Quimatryx; HDAC6 selective inhibitor - Quimatryx; IKH 02; IKH 25; IKH 35; Isoform selective HDAC inhibitor - Quimatryx; JMJ inhibitors - Quimatryx; JMJ2DC(GASC1) inhibitors - Quimatryx; Kendine 91; LFA-1 integrin inhibitor - Quimatryx; Lymphocyte function-associated antigen-1 inhibitor - Quimatryx; Nano - Quimatryx; Proteasome inhibitors - Quimatryx; QTX 100; QTX 102; QTX 125; QTX 200; QTX 300; QTX 400; Sirtuin inhibitors and activators - Quimatryx

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IkerChem
  • Developer Quimatryx
  • Class Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action DNA methylation inhibitors; Histone deacetylase inhibitors; Jumonji domain-containing histone demethylase inhibitors; Lymphocyte function-associated antigen-1 inhibitors; Methyltransferase inhibitors; Proteasome inhibitors; Sirtuin inhibitors; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; CNS disorders
  • No development reported Liver metastases

Most Recent Events

  • 17 Aug 2016 Preclinical development is ongoing for Cancer [PO] and CNS disorders [PO] in Spain (Quimatryx pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top